R. Stupp, W. Mason, and M. Van-den-bent, Radiotherapy plus Concomitant and Adjuvant Temozolomide for Glioblastoma, New England Journal of Medicine, vol.352, issue.10, pp.987-996, 2005.
DOI : 10.1056/NEJMoa043330

R. Stupp, M. Hegi, and W. Mason, Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial, The Lancet Oncology, vol.10, issue.5, pp.459-466, 2009.
DOI : 10.1016/S1470-2045(09)70025-7

K. Petrecca, M. Guiot, V. Panet-raymond, and L. Souhami, Failure pattern following complete resection plus radiotherapy and temozolomide is at the resection margin in patients with glioblastoma, Journal of Neuro-Oncology, vol.88, issue.1, pp.19-23, 2013.
DOI : 10.1007/s11060-012-0983-4

M. Glas, B. Rath, and M. Simon, Residual tumor cells are unique cellular targets in glioblastoma, Annals of Neurology, vol.68, pp.264-269, 2010.
DOI : 10.1002/ana.22036

S. Piccirillo, S. Dietz, B. Madhu, J. Griffiths, S. Price et al., Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin, British Journal of Cancer, vol.55, issue.3, pp.462-470, 2012.
DOI : 10.1038/sj.onc.1208311

U. Polanska and A. Orimo, Carcinoma-associated fibroblasts: Non-neoplastic tumour-promoting mesenchymal cells, Journal of Cellular Physiology, vol.68, issue.8, pp.1651-1658, 2013.
DOI : 10.1002/jcp.24347

A. Clavreul, C. Guette, and R. Faguer, Glioblastoma-associated stromal cells (GASCs) from histologically normal surgical margins have a myofibroblast phenotype and angiogenic properties, The Journal of Pathology, vol.9, issue.1, pp.74-88, 2014.
DOI : 10.1002/path.4332

URL : https://hal.archives-ouvertes.fr/hal-01064615

A. Clavreul, A. Etcheverry, and A. Chassevent, Isolation of a new cell population in the glioblastoma microenvironment, Journal of Neuro-Oncology, vol.68, issue.3, pp.493-504, 2012.
DOI : 10.1007/s11060-011-0701-7

URL : https://hal.archives-ouvertes.fr/inserm-00626532

L. Vindelov, I. Christensen, and N. Nissen, A Detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis, Cytometry, vol.2, issue.5, pp.323-327, 1983.
DOI : 10.1002/cyto.990030503

A. Clavreul, I. Jean, L. Preisser, A. Chassevent, A. Sapin et al., Human glioma cell culture: two FCS-free media could be recommended for clinical use in immunotherapy, In Vitro Cellular & Developmental Biology - Animal, vol.13, issue.9, pp.500-511, 2009.
DOI : 10.1007/s11626-009-9215-4

R. Prieto, J. Pascual, I. Subhi-issa, M. Jorquera, M. Yus et al., Predictive Factors for Craniopharyngioma Recurrence: A Systematic Review and Illustrative Case Report of a Rapid Recurrence, World Neurosurgery, vol.79, issue.5-6
DOI : 10.1016/j.wneu.2012.07.033

E. Abdelzaher, S. El-gendi, A. Yehya, and A. Gowil, Recurrence of benign meningiomas: predictive value of proliferative index, BCL2, p53, hormonal receptors and HER2 expression, British Journal of Neurosurgery, vol.46, issue.3, pp.707-720, 2011.
DOI : 10.1016/S0039-128X(00)00193-8

N. Hsu, P. Nien, K. Yokoyama, P. Chu, and M. Hou, High chondroitin sulfate proteoglycan 4 expression correlates with poor outcome in patients with breast cancer, Biochemical and Biophysical Research Communications, vol.441, issue.2, pp.514-522, 2013.
DOI : 10.1016/j.bbrc.2013.10.093

R. Warta, C. Herold-mende, and J. Chaisaingmongkol, Reduced promoter methylation and increased expression of CSPG4 negatively influences survival of HNSCC patients, International Journal of Cancer, vol.9, issue.11, 2014.
DOI : 10.1002/ijc.28906

A. Svendsen, J. Verhoeff, and H. Immervoll, Expression of the progenitor marker NG2/CSPG4 predicts poor survival and resistance to ionising radiation in glioblastoma, Acta Neuropathologica, vol.75, issue.7, pp.495-510, 2011.
DOI : 10.1007/s00401-011-0867-2

M. Chekenya and G. Pilkington, NG2 precursor cells in neoplasia: functional, histogenesis and therapeutic implications for malignant brain tumours, Journal of Neurocytology, vol.31, issue.6/7, pp.507-528, 2002.
DOI : 10.1023/A:1025795715377

A. Mangiola, G. Lama, and C. Giannitelli, Stem Cell Marker Nestin and c-Jun NH2-Terminal Kinases in Tumor and Peritumor Areas of Glioblastoma Multiforme: Possible Prognostic Implications, Clinical Cancer Research, vol.13, issue.23, pp.6970-6977, 2007.
DOI : 10.1158/1078-0432.CCR-07-1229

G. Sica, G. Lama, C. Anile, M. Geloso, L. Torre et al., Assessment of angiogenesis by CD105 and nestin expression in peritumor tissue of glioblastoma, International Journal of Oncology, vol.38, issue.1, pp.41-50, 2011.
DOI : 10.3892/ijo_00000822

R. Dahlrot, S. Hermansen, S. Hansen, and B. Kristensen, What is the clinical value of cancer stem cell markers in gliomas, Int J Clin Exp Pathol, vol.6, pp.334-382, 2013.

K. Hatanpaa, T. Hu, and V. Vemireddy, High expression of the stem cell marker nestin is an adverse prognostic factor in WHO grade II???III astrocytomas and oligoastrocytomas, Journal of Neuro-Oncology, vol.28, issue.1, pp.183-192, 2014.
DOI : 10.1007/s11060-014-1376-7

Z. Wang and X. Yan, CD146, a multi-functional molecule beyond adhesion, Cancer Letters, vol.330, issue.2, pp.150-62, 2013.
DOI : 10.1016/j.canlet.2012.11.049

S. Kapoor, CD146 expression and its close relationship to tumor progression in systemic malignancies besides gall bladder carcinomas, Tumor Biology, vol.27, issue.1, pp.1273-1277, 2013.
DOI : 10.1007/s13277-012-0526-9

J. Wang, A. Svendsen, and J. Kmiecik, Targeting the NG2/CSPG4 Proteoglycan Retards Tumour Growth and Angiogenesis in Preclinical Models of GBM and Melanoma, PLoS ONE, vol.4, issue.7, pp.23062-23075, 2011.
DOI : 10.1371/journal.pone.0023062.s003

Y. Matsuda, M. Hagio, and T. Ishiwata, Nestin: A novel angiogenesis marker and possible target for tumor angiogenesis, World Journal of Gastroenterology, vol.19, issue.1, pp.42-50, 2013.
DOI : 10.3748/wjg.v19.i1.42

B. Hu and S. Phan, Myofibroblasts, Current Opinion in Rheumatology, vol.25, issue.1, pp.71-78, 2013.
DOI : 10.1097/BOR.0b013e32835b1352

M. Hu, J. Yao, L. Cai, K. Bachman, F. Van-den-brûle et al., Distinct epigenetic changes in the stromal cells of breast cancers, Nature Genetics, vol.93, issue.8, pp.899-905, 2005.
DOI : 10.1038/ng1596

J. Hanson, J. Gillespie, A. Grover, M. Tangrea, R. Chuaqui et al., Gene Promoter Methylation in Prostate Tumor-Associated Stromal Cells, JNCI Journal of the National Cancer Institute, vol.98, issue.4, pp.255-61, 2006.
DOI : 10.1093/jnci/djj051

L. Jiang, T. Gonda, and M. V. Gamble, Global Hypomethylation of Genomic DNA in Cancer-Associated Myofibroblasts, Cancer Research, vol.68, issue.23, pp.9900-9908, 2008.
DOI : 10.1158/0008-5472.CAN-08-1319

W. Lee, Breast cancer cells induce stromal fibroblasts to secrete ADAMTS1 for cancer invasion through an epigenetic change, PloS One, vol.7, pp.35128-35158, 2012.

R. Adany, R. Heimer, B. Caterson, J. Sorrell, and R. Iozzo, Altered expression of chondroitin sulfate proteoglycan in the stroma of human colon carcinoma. Hypomethylation of PG-40 gene correlates with increased PG-40 content and mRNA levels, J Biol Chem, vol.265, pp.11389-96, 1990.

D. Hellebrekers, K. Castermans, and E. Viré, Epigenetic Regulation of Tumor Endothelial Cell Anergy: Silencing of Intercellular Adhesion Molecule-1 by Histone Modifications, Cancer Research, vol.66, issue.22, pp.10770-10777, 2006.
DOI : 10.1158/0008-5472.CAN-06-1609

E. Gömöri, J. Pál, B. Kovács, and T. Dóczi, Concurrent hypermethylation of DNMT1, MGMT and EGFR genes in progression of gliomas, Diagn Pathol, vol.7, issue.8, 2012.

A. Montero, C. Díaz-montero, L. Mao, E. Youssef, M. Estecio et al., Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer, Cancer Biology & Therapy, vol.5, issue.11, pp.1494-501, 2006.
DOI : 10.4161/cbt.5.11.3299

M. Scartozzi, I. Bearzi, and A. Mandolesi, Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients, British Journal of Cancer, vol.31, issue.11, pp.1786-90, 2011.
DOI : 10.1073/pnas.81.23.7308

E. Román-pérez, P. Casbas-hernández, J. Pirone, J. Rein, L. Carey et al., Gene expression in extratumoral microenvironment predicts clinical outcome in breast cancer patients, Breast Cancer Research, vol.6, issue.2, pp.51-87, 2012.
DOI : 10.1371/journal.pone.0018196

M. Al-rakan, D. Colak, S. Hendrayani, A. -. Bakheet, A. Mohanna et al., Breast stromal fibroblasts from histologically normal surgical margins are pro-carcinogenic, The Journal of Pathology, vol.367, issue.4, pp.457-65, 2013.
DOI : 10.1002/path.4256

URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4284036

D. Bonis, P. Anile, C. Pompucci, A. Fiorentino, A. Balducci et al., The influence of surgery on recurrence pattern of glioblastoma, Clinical Neurology and Neurosurgery, vol.115, issue.1, pp.37-43, 2013.
DOI : 10.1016/j.clineuro.2012.04.005

B. Pirotte, M. Levivier, S. Goldman, N. Massager, D. Wikler et al., Positron Emission Tomography-guided Volumetric Resection of Supratentorial High-grade Gliomas: A Survival Analysis in 66 Consecutive Patients, Neurosurgery, vol.64, issue.3, pp.471-81, 2009.
DOI : 10.1227/01.NEU.0000338949.94496.85

W. Stummer, U. Pichlmeier, T. Meinel, O. Wiestler, F. Zanella et al., Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial, The Lancet Oncology, vol.7, issue.5, pp.392-401, 2006.
DOI : 10.1016/S1470-2045(06)70665-9

G. Aldave, S. Tejada, E. Pay, M. Marigil, B. Bejarano et al., Prognostic Value of Residual Fluorescent Tissue in Glioblastoma Patients After Gross Total Resection in 5-Aminolevulinic Acid-Guided Surgery, Neurosurgery, vol.72, issue.6, pp.915-935, 2013.
DOI : 10.1227/NEU.0b013e31828c3974